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1 
2 
3 ABSTRACT 
4 
5 Mutations in the UMOD gene coding for uromodulin cause autosomal dominant 
6 
7 tubulointerstitial kidney disease. Uromodulin is known to regulate transport processes in the 
8 
9 
thick ascending limb, but it remains unknown whether UMOD mutations are associated with 
11 
12 functional tubular alterations in the early phase of the disease. 
13 
14 The responses to furosemide and to a water deprivation test were compared in a 32-year-old 
15 
16 female patient carrying the pathogenic UMOD mutation p.C217G and her unaffected 31-year- 
17 
18 
old sister. A single dose of furosemide induced an intense headache with exaggerated 
19 
20 
21 decrease in blood pressure (∆ syst: 30 vs. 20mmHg; ∆ diast: 18 vs. 5mmHg) and body weight 
22 
23 (∆ 2.6kg vs. ∆ 0.9kg over 3h) in the proband vs. unaffected sib. The diuretic response and the 
24 
25 fall in urine osmolality were also more important and detected earlier in the affected sib. 
26 
27 Water deprivation led to increased plasma osmolality and urine concentration in both siblings; 
28 
29 
however, the response to desmopressin was attenuated in the affected sib. These data reveal 
31 
32 that mutations of uromodulin cause specific transport alterations, including exaggerated 
33 
34 response to furosemide and a failure to maximally concentrate urine, in the early phase of the 
35 
36 disease. 
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1 
2 
3 INTRODUCTION 
4 
5 Uromodulin (Tamm-Horsfall protein) is exclusively produced in the epithelial cells 
6 
7 lining the thick ascending limb (TAL) of Henle’s loop and is the most abundant protein in the 
8 
9 
normal urine. Evidence obtained from in vitro studies and knock-out mouse studies have 
11 
12 shown that uromodulin protects against urinary tract infection and kidney stones, and 
13 
14 regulates transport systems operating in the TAL (1). The latter include the sodium-chloride 
15 
16 cotransporter NKCC2 and the potassium channel ROMK, which operate in parallel and are 
17 
18 
essential to reabsorb 25% of the filtered NaCl and to mediate the urinary concentrating ability 
19 
20 
21 (2). 
22 
23 Mutations in the UMOD gene encoding uromodulin have been shown to cause 
24 
25 medullary cystic kidney disease type 2 (MCKD2; MIM 603860), familial juvenile 
26 
27 hyperuricemic nephropathy (FJHN; MIM 162000) and glomerulocystic kidney disease 
28 
29 
(GCKD; MIM 609886) (3-5) which are collectively referred to as uromodulin-associated 
31 
32 kidney diseases (UAKD). UAKD are autosomal dominant disorders characterised by 
33 
34 hyperuricemia and gout early in life, alteration of urinary concentrating ability, and tubulo- 
35 
36 interstitial fibrosis with occasional cysts at the cortico-medullary junction (1). UAKD 
37 
38 
invariably lead to chronic renal failure during the third to seventh decade of life (6). There is 
39 
40 
41 no specific therapy to slow renal disease progression, and most patients end up with ESRD. 
42 
43 The fact that hyperuricemia is the most consistent feature observed  in patients 
44 
45 harbouring UMOD mutations has led to suggest that the disease causes a dysfunction of the 
46 
47 TAL, with NaCl-loss and secondary reabsorption of uric acid in the proximal tubule (6,7). 
48 
49 
This hypothesis has been supported by functional defects evidenced in the first transgenic 
51 
52 mouse model of disease (8). However, the existence of a specific dysfunction of the TAL as 
53 
54 an early consequence of defective uromodulin processing has not been evaluated in patients 
55 
56 harbouring a pathogenic UMOD mutation. 
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1 
2 
3 To investigate whether a pathogenic UMOD mutation is associated with functional 
4 
5 alterations in the TAL in the early stage of the disease, we performed a family-based study to 
6 
7 compare the response to a furosemide test and to a water-deprivation test with administration 
8 
9 
of desmopressin in a proband carrying a pathogenic mutation of UMOD and her unaffected 
11 
12 sister. 
13 
14 
15 
16 PATIENTS AND METHODS 
17 
18 
The proband, a 32-year-old female harbouring a missense (p.C217G) mutation in the 
19 
20 
21 UMOD gene (III,2), and her 31-year-old sister tested negative for the mutation (III,4) belong 
22 
23 to a four-generation family. The pathogenic nature of the p.C217G mutation of UMOD was 
24 
25 evidenced by the typical course of UAKD observed in the other sister of the proband (III,3) 
26 
27 who reached end-stage renal disease at age 37 years (Fig. 1A). The proband and her 
28 
29 
unaffected sister had an eGFR (CKD-EPI) ≥ 60 ml/min/1.73 m² at time of testing, and none of 
31 
32 them was diabetic. They were not taking any drug, including diuretics, allopurinol, or 
33 
34 antihypertensive medications. The protocol was approved by the Ethical Committee of the 
35 
36 UCL Medical School (Brussels), and informed consent was provided. 
37 
38 
A 24-h urine collection was obtained in both sisters immediately before the 
39 
40 
41 furosemide test. The day of the furosemide test, a baseline clinical and biological evaluation 
42 
43 was performed at 9:30 AM, 4h before giving a single oral dose of 80 mg furosemide. Baseline 
44 
45 values for the furosemide test (Fig. 1B) correspond to a 3-h urine collection preceding 
46 
47 immediately the administration of furosemide. After furosemide administration, urine samples 
48 
49 
were collected hourly during 3 h and analysed for Na
+ 
and K
+
, creatinine, urea and uric acid 
51 
52 concentrations, osmolality and pH. Clinical and biological evaluations were repeated at the 
53 
54 end of the test (time +3h; see Table 1). The following day (i.e. after 18h of normal hydration), 
55 
56 both individuals underwent a 8-h water deprivation test, including a 30-min intravenous 
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1 
2 
3 infusion of desmopressin acetate (Minirin
R
, 0.3 µg/kg; Ferring AG, Baar, Swizerland) after 6 
4 
5 h of water deprivation. Desmopressin (or deamino-8D-arginine vasopressin, dDAVP) is a 
6 
7 
peptidic analogue of endogenous antidiuretic hormone (ADH) with a higher affinity for V2 
8 
9 
10 receptors and negligible vasopressive potential. A clinical evaluation was performed hourly 
11 
12 and plasma and urine samples were taken every 2 h during the water deprivation and 60 and 
13 
14 120 min after initiation of desmopressin perfusion. Dietary intake was identical in the two 
15 
16 
sisters before the furosemide test and throughout the water deprivation test. 
17 
18 
19 
20 
21 RESULTS 
22 
23 
24 The baseline osmolar balance in the two sisters immediately before the functional tests 
25 
26 
was similar, thus allowing direct interindividual comparison of the responses to furosemide 
27 
28 
and to water restriction (Values for affected sib vs. control sib: 24h Na
+ 
excretion: 228 mmol 
30 
31 vs. 307 mmol; 24h urea excretion: 29.1g vs. 23.1g; osmolar excretion rate: 779.2 µosm/min 
32 
33 vs. 787.5 µosm/min; plasma renin activity: 1.1 ng/mL/h vs. 0.8 ng/mL/h; plasma aldosterone: 
34 
35 0.31 nM vs. 0.30 nM, respectively. Plasma ADH: <0.2 pg/mL in both sibs). 
36 
37 
The furosemide test was poorly tolerated by the proband, who reported intense 
38 
39 
40 headhache, a severe drop in blood pressure (∆30/∆18 mmHg vs. ∆20/∆5 mmHg in the 
41 
42 unaffected sister) and a weight loss of 2.6 kg (vs. weight loss of 0.9 kg in the unaffected 
43 
44 sister) in 3 h (Table 1). After furosemide administration, both siblings showed the expected 
45 
46 
increase in diuresis with concomitant fall in urine osmolality. However, the changes were 
47 
48 
49 more important and were detected earlier in the proband, who also showed a more 
50 
51 pronounced and earlier increase of fractional excretion of Na
+ 
than the control sibling (Fig. 
52 
53 1B). 
54 
55 The water deprivation test was well tolerated by both participants. Blood pressure and 
56 
57 
weight remained constant during all the procedure. As expected, water deprivation resulted in 
57 
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1 
2 
3 a progressive increase in plasma osmolality with an increased urine osmolality and a reduced 
4 
5 urine flow in both subjects (Fig. 1B). The response to desmopressin was normal in the control 
6 
7 sibling, with an increase in urine osmolality (from 983 to 1124 mOsm/kg H2O, 2h after 
8 
9 
infusion), a decrease in urine flow (from 30 to 18 mL/h), and a decrease in plasma osmolality 
11 
12 (from 298 to 295 mOsm/kg H2O). In contrast, the affected sib showed a blunted increase in 
13 
14 urine osmolality (from 834 to 869 mOsm/kg H2O), an increase in urine flow (from 17.5 mL/h 
15 
16 to 20 mL/h), and a paradoxical increase in plasma osmolality (from 298 to 305 mOsm/kg 
17 
18 
H O) (Fig. 1B). 
19 
20 
21 Pathology examination of the end-stage kidney biopsy of patient (III,3) (Fig. 1C) 
22 
23 revealed marked tubulo-interstitial lesions, with thickening of the tubular basement membrane 
24 
25 and abnormal processing and accumulation of uromodulin in the tubular cells. Of note, there 
26 
27 was no detectable immunostaining for NKCC2 in the biopsy. 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
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1 
2 
3 DISCUSSION 
4 
5 In this study, we performed a sib-pair functional testing to evaluate whether 
6 
7 pathogenic mutations of UMOD are associated with dysfunction of the TAL in the early phase 
8 
9 
of UAKD. Our data reveal that the proband carrying a UMOD mutation shows a clinically 
11 
12 and biologically exaggerated response to furosemide and a failure to maximally concentrate 
13 
14 urine after desmopressin administration. To the best of our knowledge, this is the first report 
15 
16 of abnormal tubular functional testing in a subject harbouring a pathogenic UMOD mutation. 
17 
18 
Several lines of evidence suggest that uromodulin plays an important role in regulating 
19 
20 
21 NKCC2 and ROMK in the TAL (9-11). These two transport processes mediate the 
22 
23 furosemide-sensitive NaCl reabsorption and the generation of the osmotic gradient which 
24 
25 drives the urine concentrating ability. Patients with UMOD mutations are characterized by an 
26 
27 early defect in urine concentration (3-5), which could be paralleled with a discrete NaCl- 
28 
29 
losing phenotype explaining hyperuricemia (6,7). Studies of mice harbouring a pathogenic 
31 
32 mutation of uromodulin revealed that the urinary concentrating defect precedes renal failure 
33 
34 and is related to a specific defect in the TAL (8). The latter includes defective expression of 
35 
36 NKCC2 and other markers, secondary to the accumulation of mutant uromodulin in the 
37 
38 
endoplasmic reticulum (ER) (8). We confirm such lesions in the end-stage kidney biopsy of 
39 
40 
41 patient III,3, showing extensive tubulo-interstitial damage with abnormal processing of 
42 
43 uromodulin and loss of NKCC2 immunoreactivity. 
44 
45 The demonstration of an exaggerated response to furosemide in the proband, despite 
46 
47 the lower eGFR than her control sister, is of particular interest. Since uromodulin expression 
48 
49 
levels regulate NKCC2 activity (10, 11), it is conceivable that the reduced trafficking of 
51 
52 native uromodulin in UAKD might lead to a decreased amount of active NKCC2 on the apical 
53 
54 cell membrane. This effect would be amplified by the fact that disease-causing UMOD 
55 
56 mutations also lead to decreased surface expression of ROMK (9). The paradoxically 
57 
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1 
2 
3 increased response to furosemide, as observed here, might therefore indicate that there is still 
4 
5 sufficient NaCl uptake capacity (e.g. due to hyperactivated residual NKCC2) to maintain a 
6 
7 steady-state in the early stage of disease. Administration of furosemide may disrupt this 
8 
9 
equilibrium, by inhibiting active NKCC2 transporters with no immediately available 
11 
12 compensation in other tubule segments. The normal serum uric acid levels (Table 1) and the 
13 
14 slightly higher uric acid fractional excretion in the proband (5.9% vs. 5.1% in the healthy sib 
15 
16 calculated from the baseline 3-h urine collection) may indeed suggest a maintained sodium 
17 
18 
balance by residual TAL function without proximal compensatory adaptation. 
19 
20 
21 Alternatively, the exaggerated response to furosemide in the proband with early 
22 
23 UAKD could unmask a shift of steady- state NaCl reabsorption inside the TAL. Based on 
24 
25 functional and anatomical differences, the TAL segment could indeed be sub-divided into a 
26 
27 cortical (cTAL) and a medullary (mTAL) portion. The cTAL, which lies in an environment 
28 
29 
isosmotic to the plasma, is responsible for the majority of NaCl reabsorption and is the true 
31 
32 “diluting segment” of the nephron (12, 13). In the rat kidney, two different cell types coexist 
33 
34 in the TAL: cells with a smooth surface and a dense subapical NKCC2-containing vesicle 
35 
36 pool, which predominate in the mTAL, and cells with a rough surface and a much less 
37 
38 
abundant vesicle system, which largely dominate in the cTAL (14). Although human UMOD 
39 
40 
41 transcript levels have been found quite similar in mTAL and cTAL (15), human uromodulin 
42 
43 protein levels were 4-fold greater in the TAL-enriched outer medulla than in the cortex by 
44 
45 immunoblotting (16). In healthy individuals, steady state NaCl reabsorption is probably 
46 
47 achieved by the early part of cTAL, leaving a "physiological reserve" in the late part of the 
48 
49 
cTAL (12). In the proband with early UAKD, a reduced function of NKCC2 in mTAL could 
51 
52 be compensated by a larger implication of the cTAL, possibly spared from the transport 
53 
54 alterations associated with UAKD. Thus, a shift of NaCl reabsorption to downstream/late part 
55 
56 of the cTAL may have used up the “physiological reserve” in the affected sib, which could 
57 
58 
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1 
2 
3 then contribute to the differential response to furosemide. The fact that, in contrast to the 
4 
5 control sib, the proband was unable to lower its urinary sodium concentration below plasma 
6 
7 sodium (data not shown) might further indicate that the diluting function of the TAL was 
8 
9 
completely abolished by furosemide. Taken together, these data indicate that the response to 
11 
12 furosemide in UAKD patients is diphasic, with an exaggerated response in early disease and 
13 
14 an anticipated loss of response as predicted by the loss of NKCC2 in end-stage kidney. Loop 
15 
16 diuretics in these patients should thus be managed with great caution. 
17 
18 
At baseline, the proband showed a trend for increased plasma osmolality contrasting 
19 
20 
21 with lower urine osmolality, compatible with a slight alteration of water homeostasis. The 
22 
23 observation of a preserved response to water deprivation followed by a blunted response to 
24 
25 desmopressin may again indicate a reduced “physiological reserve” of the urinary 
26 
27 concentrating ability in early UAKD. The normal response of the proband to water 
28 
29 
deprivation is distinct from the severe nephrogenic diabetes insipidus observed in the 
31 
32 transgenic mutant mouse model (8). The difference is probably due to the fact that the tubular 
33 
34 and interstitial lesions observed in the patient are less severe than in the transgenic mice 
35 
36 analysed at a late stage of the disease. Additionally the water restriction test challenges mostly 
37 
38 
the inner medulla with its ADH-sensitive urea transporters in the terminal collecting duct, 
39 
40 
41 where uromodulin expression is absent (13). Possible explanations for the blunted response to 
42 
43 desmopressin include (i) a failure to increase or maintain interstitial medullary 
44 
45 hyperosmolality; and/or (ii) a decreased response to desmopressin. A less active osmolar 
46 
47 gradient generator, namely NKCC2 transporter, or a leaky TAL allowing water influx into the 
48 
49 
interstitium or NaCl backleak into the lumen could underlie the former hypothesis. 
51 
52 Considering the interactions of UMOD with NKCC2 and the physical properties (including 
53 
54 water impermeability) of uromodulin polymers formed under specific ionic conditions (1), an 
55 
56 altered interstitial osmolality could be very well explained by a reduced excretion of 
56 
57 
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1 
2 
3 uromodulin. In fact, the Umod KO mice showed no increase in pNKCC2 after stimulation 
4 
5 with dDAVP, suggesting that uromodulin is important for the TAL sensitivity to vasopressin 
6 
7 (10). 
8 
9 
The main limitations of this study include the small number of siblings involved and 
11 
12 the lack of histopathology data in the early stage of disease. However, we feel that these 
13 
14 observations give insights into the biology of uromodulin and the pathophysiology of UAKD. 
15 
16 We investigated a patient with preclinical disease, with presumably limited interstitial 
17 
18 
inflammation/fibrosis (normal urinary sediment), and an unaffected sibling of the same 
19 
20 
21 gender and similar age. The deleterious effect of the mutation was evidenced by the end-stage 
22 
23 kidney biopsy of a third sibling. 
24 
25 In conclusion, our study suggests that, in the early phase of UAKD, the lack of 
26 
27 functional uromodulin leads to a discrete dysfunction of the TAL, with maintenance of a 
28 
29 
precarious clinical equilibrium that can be disturbed by specific testing. As the disease 
31 
32 progresses, the aggravation of the tubulo-interstitial lesions leads to overt tubular dysfunction 
33 
34 and compensatory mechanisms, culminating with chronic kidney disease. 
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 Proband (III,2) 
Furosemide 
Baseline  +3h 
Unaffected Sib (III,4) 
Furosemide 
Baseline  +3h 
Weight (kg) 
 
Blood pressure (mmHg) 
 
eGFR (CKD-EPI; mL/min/1.73m
2
) 
 
Plasma  Urea (mg/dL) Plasma 
Sodium (mmol/L) Plasma 
Potassium (mmol/L) Plasma 
Uric Acid (mg/dL) Plasma 
Osmolality (mOsm/L) Plasma 
Bicarbonate (mmol/L) 
76.1 73.5 
 
140/90 110/72 
 
60 60 
 
45 43 
 
141 138 
 
4.4 3.7 
 
6.3 6.3 
 
298 298 
 
27.5 29.5 
81.1 80.2 
 
135/80 115/75 
 
99 99 
 
25 23 
 
139 138 
 
3.8 3.8 
 
6.4 6.4 
 
287 288 
 
22.5 27.5 
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1 
2 
3 Table 1. Clinical and biological response to furosemide in the proband and the unaffected 
4 
sibling. 
6 The parameters were similarly recorded 4 h before (Baseline) and 3 h after furosemide 
7 
8 administration (Furosemide +3h). 
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cells displaying the normal apical staining for uromodulin (arrowhead). There is no detectable 
 
immunostaining for NKCC2 (panel c) in the kidney of patient (III,3) as compared with normal 
staining pattern (inset). 
Original magnifications: a, x350; b, x200, c, x700. 
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1 
2 
3 Figure Legends 
4 
5 
6 Figure 1. Pedigree of the family, UMOD mutation, response to furosemide and water 
7 
8 deprivation and end-stage  kidney biopsy. 
9 
A. Pedigree of the family and UMOD mutation. Individuals with a history of renal disease 
11 are depicted by black symbols. Circles denote females, squares males. The proband carrying 
12 
13 the UMOD mutation (III,2) and her unaffected sister (III,4) are marked by an arrow and an 
14 
arrowhead, respectively. Individuals tested for mutation are tagged by an asterisk (*). Patient 
16 III,3 showed a typical course of uromodulin-associated kidney disease, with hyperuricemia at 
17 
18 age 21 years and end-stage renal disease at age 37 years. Sequence analysis of the UMOD 
19 
gene revealed a thymine to guanine transition at nucleotide 794 resulting in the substitution of 
21 a  well conserved cysteine by a glycine at position 217 (p.C217G). Encoded amino acid 
22 
23 sequence is indicated above the DNA sequence. Mutated nucleotide is boxed. The mutation 
24 
25 has been previously reported by Dahan et al. (4). 
26 B. Biological parameters at baseline and evoluation after furosemide administration and 
27 
28 water deprivation with desmopressin perfusion.  The patient harbouring the UMOD mutation 
29 
30 is indicated by red dots and her unaffected sister by blue squares. Baseline values in the 
31 furosemide test have been obtained from a 3-hour urine collection immediately preceding 
32 
33 furosemide administration. This same baseline diuresis has been plotted in the water 
34 
35 deprivation test curve. Urine and plasma osmolality values at time 0 of the water deprivation 
36 test provide from urine and blood sample collected before the test. 
37 
38 C. End-stage  kidney biopsy from patient (III,3) harbouring the p.C217G UMOD mutation. 
39 
40 Hematoxylin-eosine staining (panel a) reveals interstitial fibrosis and tubular atrophy with 
41 abundant inflammatory infiltrate and the characteristic thickening of the tubular basement 
42 
43 membrane (inset, arrows). Immunostaining (panel b) reveals diffuse intracellular 
44 
45 accumulation of uromodulin in a subset of cells lining enlarged tubules (arrow) as well as 
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